

**GOVERNMENT OF INDIA  
MINISTRY OF CHEMICALS AND FERTILIZERS  
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA  
UNSTARRED QUESTION No. 2983  
TO BE ANSWERED ON THE 17<sup>TH</sup> MARCH, 2023

**PLIs for Pharmaceutical Sector**

**2983. SHRI THIRUMAAVALAVAN THOL:**

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) whether the Productions Linked Incentive Scheme (PLIS) for Pharmaceutical sector was announced by the Government and if so, the details thereof;
- (b) whether the Government has the details of the pharmaceutical companies which have been benefitted by the PLIS and if so, the details thereof;
- (c) the details of Critical Key Starting Materials/ Drug intermediates/Active Pharmaceutical Ingredients the production of which have been increased or/and expected to be increased further; and
- (d) the details of amount of funds disbursed to pharmaceutical companies by way of incentive, since the launch of PLIS?

**ANSWER**

**MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS  
(SHRI BHAGWANTH KHUBA)**

---

(a) to (d): The Government of India has taken several measures to encourage domestic manufacturing of Pharmaceutical drugs including bulk drugs and Medical Devices to reduce import dependence and to establish a dominant position in the global market. The Programmatic interventions to support Pharma Industries as on date are as follows;

- i. Under the *Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India*, with a financial outlay of Rs. 6,940 crores and the tenure from FY 2020-2021 to FY 2029-30, the financial incentive is planned to be provided for 41 identified products. A total of 51 applications have been selected under the scheme. Out of these, 22 projects have already been commissioned with the installed capacity of 34,255 MT. As per the information submitted by the applicants on the sales for the period from April 2022 to December 2022, a total sale of 3972.55 MT of 12 Bulk Drugs covered under the scheme, with a value of Rs.389.89 Cr has been reported. The details of Critical KSMs / DIs /APIs Ingredients approved under the scheme, whose production is expected to increase, are given and sales details of 12 bulk drugs are given at **Annexure-1**.
- ii. *PLI Scheme for Pharmaceuticals*, with a financial outlay Rs. 15,000 crores and the tenure from FY 2020- 2021 to FY 2028-29, provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of

six years. This scheme also covers the APIs, other than those covered under the PLI scheme under Bulk Drugs as mentioned at Point (i).

- iii. *PLI Scheme for Promoting Domestic Manufacturing of Medical Devices* with total financial outlay of Rs. 3,420 crore and tenure from FY 2020-2021 to FY 2027-28, provides incentive to selected companies at the rate of 5% on incremental sales of medical devices manufactured in India and covered under the four Target segments of the scheme, for a period of five (5) years. 26 applicants have been approved and fourteen projects have been commissioned so far.

FY 2022-23 is the first year of production for all the three PLI schemes, except fermentation based products under PLI Scheme for Bulk Drugs, for which, FY 2023-24 is the first year of Production. As on date, *under the PLI scheme for Pharmaceuticals*, an incentive amount of Rs.363 Cr has been released under the scheme.

The list of applicant firms selected under these three PLI schemes are available in the Department website at <https://pharmaceuticals.gov.in/schemes> under the respective PLI scheme.

**Annexure-I**

**Details of Critical KSMs / DIs / APIs Ingredients approved under PLI scheme for Promotion of Domestic Manufacturing of Critical KSMs / DIs / APIs in India**

<b>Sl. No.</b>	<b>Target Segment or Category of KSMs / DIs / APIs</b>	<b>Products approved under the PLI scheme</b>
1.	<b>Key Fermentation Based KSMs /Drug Intermediates</b>	Penicillin G, 7 – ACA and Clavulanic Acid
2.	<b>Fermentation Based Niche KSMs / Drug Intermediates / APIs</b>	Betamethasone, Dexamethasone, Prednisolone, Rifampicin and Clindamycin Base.
3.	<b>Key Chemical Synthesis Based KSMs/Drug Intermediates</b>	1,1 Cyclohexane Diacetic Acid (CDA), Para amino phenol and Dicyandiamide (DCDA)
4.	<b>Other Chemical Synthesis Based KSMs/Drug Intermediates/APIs</b>	Meropenem, Atorvastatin, Olmesartan, Aspirin, Ritonavir, Lopinavir, Acyclovir, Carbamazepine, Oxcarbazepine, Vitamin B6, Valsartan, Losartan, Levofloxacin, Ofloxacin, Diclofenac Sodium, Carbidopa, Levodopa, Sulfadiazine, Ciprofloxacin, Vitamin B1, Telmisartan, Levetiracetam, Norfloxacin and Artesunate

**Details of the Sales reported by the PLI applicants under PLI scheme for Promotion of Domestic Manufacturing of Critical KSMs / DIs / APIs in India**

<b>S. No.</b>	<b>Product</b>	<b>Total Sales (Apr 22 – Dec 22) (₹ in crore)</b>	<b>Total Sales Quantity (Apr 22 - Dec 22) (MT)</b>
1	1,1 Cyclohexane Diacetic Acid (CDA)	2.62	28.54
2	Para Amino Phenol	177.97	3,695.00
3	Para Amino Phenol	31.95	0.33
4	Sulfadiazine	26.79	115.63
5	Telmisartan	2.81	4.48
6	Atorvastatin	86.85	66.97
7	Carbamazepine	0.39	0.47
8	Oxcarbazepine	47.95	41.68
9	Norfloxacin	0.20	0.58
10	Ofloxacin	0.91	2.66
11	Carbidopa	0.15	0.03
12	Levofloxacin	11.31	16.20
<b>Total</b>		<b>389.89</b>	<b>3,972.55</b>

\*\*\*\*\*